Floatz logo

Atogepant

Migraine Disorder

Stanford UniversitySmall moleculePhase 4 / ApprovedActive
A
87/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
85/ 100
Competitive Position
89/ 100

Competitive context

100 Active assets in the Migraine Disorder cohort.

Asset / SponsorPhaseRating
Zolmitriptan
Zosano Pharma Corporation
Phase 4A
Naproxen
IRCCS San Raffaele Roma
Phase 4A
Rizatriptan
Antonios Likourezos
Phase 4A
DFN-11 (SUMATRIPTAN INJECTION)
IRCCS San Raffaele Roma
Phase 4BBB
Eptinezumab
Stanford University
Phase 4BBB

View all 50 →

Same molecule, other indications

Atogepant is also rated in:

tinnitusActive
B
Indicative · Phase 4
62 / 100
View asset →
overactive bladderActive
D
Indicative · Unknown
30 / 100
View asset →
interstitial cystitisActive
D
Indicative · Unknown
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →